Ainos, Inc. (AIMD)
Ainos, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Houston, TX, US. The stock last traded at $1.46, down 1.35% on the session, giving a market capitalisation of $10.8M. On trailing twelve-month figures it carries a trailing P/E of -0.58, a net margin of -106283.3%. Its beta of 2.48 implies it has historically moved more than the broad market.
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Ainos, Inc. is most often compared with the following Healthcare names: